🟢 positive (FOLLOW) · 🟡 wait (WAIT) · 🔴 bad/avoid (FADE/AVOID) · 🚨 major news
The U.S. stock market just had a strong session, with the S&P 500 up 2.3% and the Nasdaq up 2.7%. This suggests market sentiment is positive.
Hot topics:
🚨 🟢 MRNA — Moderna awaits approval for its cancer therapy, a significant advance in healthcare.
🚨 🟢 ABT — Abbott scores an FDA win and launches Oncodetect, demonstrating the company’s competitive strength.
🚨 🟡 MRK — Merck awaits news on its Ebola vaccine; this uncertainty could affect the stock price.
🚨 🟡 PFE — Moderna seeks approval for a cancer therapy; this is a major event in healthcare.
🟢 LLY — Eli Lilly announces Phase 3 trial results for Foundayo; these results could affect the company's outlook.
Use caution:
🔴 NVO — FDA calls for a vision-loss warning; this is a negative signal for the company.
🚨 BIG NEWS — MRNA: MODERNA AWAITS APPROVAL FOR CANCER THERAPY.
🟢 MRNA — HEALTHCARE-FDA — FOLLOW
Key news: Moderna awaits FDA approval for its cancer therapy in 2027.
Implication: Potential impact on Moderna revenue if the cancer therapy receives FDA approval.
Action (1D): confirm on close above 280.8 (52-week high) · invalidated on close below 265.8 (upper BB) · price 269.0 · RSI14/50/99 67/65/65
Source: Yahoo Finance 10/11, The Business Journals 06/11, Quiver Quantitative 06/11, TradingView 06/11
🚨 BIG NEWS — ABT: ABBOTT WINS AT THE FDA.
🟢 ABT — HEALTHCARE-FDA — FOLLOW
Key news: Abbott wins at the FDA and launches Oncodetect.
Implication: Potential impact on Abbott revenue following its FDA win and launch of a new product.
Action (1D): confirm on close above 114.0 (upper BB) · invalidated on close below 105.9 (middle BB) · price 110.5 · RSI14/50/99 59/55/55
Source: Simply Wall St 10/11, ad-hoc-news.de 09/11, Simply Wall St 08/11
🚨 BIG NEWS — MRK: MERCK AWAITS NEWS ON EBOLA VACCINE.
🟡 MRK — HEALTHCARE-FDA — WAIT
Key news: Merck awaits news on widespread use of its Ebola vaccine.
Implication: Potential impact on Merck revenue if the Ebola vaccine is widely used.
Action (1D): bullish on close above 151.8 (upper BB) · bearish on close below 146.4 (MA50) · price 148.8 · RSI14/50/99 54/55/62
Source: Yahoo Finance 10/11, Bloomberg.com 10/11
🚨 BIG NEWS — PFE: MODERNA SEEKS APPROVAL FOR CANCER THERAPY.
🟡 PFE — HEALTHCARE/FDA — WAIT
Key news: Moderna files for FDA approval of its first cancer therapy.
Implication: Potential impact on PFE revenue if Moderna receives approval.
Action (1D): bullish on close above 29.80 (middle BB) · bearish on close below 28.77 (MA50) · price 29.23 · RSI14/50/99 48/55/65
Source: Yahoo Finance 10/11, Kalkine 09/11
🟢 LLY — HEALTHCARE/FDA — FOLLOW
Headline: Eli Lilly announces Phase 3 trial results.
Key news: Eli Lilly announces Phase 3 trial results for Foundayo.
Implication: Potential impact on LLY revenue from positive trial results.
Action (1D): confirm on close above 1461.8 (upper BB) · invalidated on close below 1313.4 (middle BB) · price 1411.9 · RSI14/50/99 68/62/62
Source: BigGo Finance 10/11, GuruFocus 10/11, Blockonomi 10/11, Yahoo Finance 10/11, Yahoo Finance 09/11
🟡 JNJ — HEALTHCARE/FDA — WAIT
Headline: Johnson & Johnson receives FDA approval for RYBREVANT FASPRO.
Key news: Johnson & Johnson receives FDA approval for RYBREVANT FASPRO.
Implication: Potential impact on JNJ revenue from FDA approval.
Action (1D): bullish on close above 284.0 (upper BB) · bearish on close below 266.1 (MA50) · price 282.1 · RSI14/50/99 64/58/62
Source: Quantisnow 06/11, Yahoo Finance 09/11
🔴 NVO — HEALTHCARE/FDA — FADE
Headline: FDA calls for vision-loss warning.
Key news: FDA calls on Novo Nordisk and Eli Lilly to add vision-loss warnings to GLP-1 drugs.
Implication: Potential negative impact on Novo Nordisk revenue from having to add vision-loss warnings to GLP-1 drugs.
Action (1D): confirm on close below 40.50 (MA50) · invalidated on close above 41.58 (upper BB) · price 41.38 · RSI14/50/99 58/50/62
Source: Yahoo Finance 10/11, Yahoo Finance 09/11
🟢 TEM — HEALTHCARE/FDA/PARTNERSHIP — FOLLOW
Headline: Tempus partners with SOTERIA.
Key news: Tempus partners with SOTERIA to advance precision oncology.
Implication: Potential positive impact on Tempus revenue from partnering with SOTERIA to advance precision oncology.
Action (1D): confirm on close above 89.09 (52-week high) · invalidated on close below 82.61 (upper BB) · price 84.44 · RSI14/50/99 62/57/54
Source: Yahoo Finance 10/11, Form 4/SEC
🟢 VKTX — HEALTHCARE/FDA — FOLLOW
Headline: Viking Therapeutics moves closer.
Key news: Viking Therapeutics moves closer to challenging Ozempic with progress in its Phase 3 trial.
Implication: Potential positive impact on Viking Therapeutics revenue from progress in its Phase 3 trial.
Action (1D): confirm on close above 29.73 (MA50) · invalidated on close below 28.58 (upper BB) · price 28.99 · RSI14/50/99 55/49/58
Source: Stocktwits 08/11
🟢 AZN — LEGAL-APPROVAL — FOLLOW
Headline: AstraZeneca receives new license
Key news: AstraZeneca receives a C4XD license for its pipeline program.
Implication: Potential positive impact on revenue as AstraZeneca can develop additional new products.
Action (1D): confirm on close above 194.5 (upper BB) · invalidated on close below 180.2 (MA200) · price 189.4 · RSI14/50/99 71/58/58 (RSI14 overbought)
Source: ad-hoc-news.de 09/11, The Mighty 790 KFGO 05/11
🟡 ABCL — HEALTHCARE-FDA — WAIT
Headline: AbCellera Biologics reports strong trial data
Key news: AbCellera Biologics reports positive trial data.
Implication: Potential positive impact on revenue as AbCellera Biologics may develop new products based on strong trial data, but further FDA results are awaited.
Action (1D): bullish on close above 13.40 (upper BB) · bearish on close below 12.30 (MA50) · price 12.50 · RSI14/50/99 52/55/56
Source: Simply Wall St 10/11
⚠️ Based only on NEWS HEADLINES (Yahoo/Google News RSS). Insider stock sales are often made under prearranged plans. Not investment advice.
⚠️ Not investment advice.📊🪙Finance Trader🪙📊“Do less, make more money. It’s all about efficiency”🗽💰TraderKA_M8Capital